Fenwick represented Third Harmonic Bio, Inc. on the deal.Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
